Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-09: Form 8-K; Period of report 2020-12-07; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 3.01.
- 2020-11-09: Form 8-K; Period of report 2020-11-09; Description 2.02 Results of Operations and Financial Condition; 8.01 Other Events; Details 2.02.
- 2020-09-29: Form 8-K; Period of report 2020-09-29; Description 8.01 Other Events; Details 8.01.
- 2020-08-25: Form 8-K; Period of report 2020-08-24; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-09 | 8-K | 2020-12-07 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 7.01 Regulation FD Disclosure; 8.01 Other Events | 3.01 On December 7, 2020, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the Company no longer complies with Nasdaq’s Listing Rule 5605(c)(2)(A) (the “Audit Composition Rule”) following the death of Dr. Michael Venuti, a member of the Company’s Board of Directors (the “Board) and the Audit Committee of the Board (the “Audit Committee”). 7.01 On December 9, 2020, the Company intends to present a slide presentation on a conference call reviewing data from MARIO-3, the Company’s Phase 2 clinical trial evaluating eganelisib in a triple combination in the front-line setting with Tecentriq® (atezolizumab) and Abraxane® (nab-paclitaxel) in patients with unresectable locally advanced or metastatic triple negative breast cancer. 8.01 On December 9, 2020, the Company issued a press release announcing data from MARIO-3. | infi-20201207.htm |
| 2020-11-09 | 8-K | 2020-11-09 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On November 9, 2020, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended September 30, 2020 and will conduct a previously announced, publicly available conference call to discuss those results. 8.01 On November 9, 2020, the Company issued a press release announcing new data from MARIO-1, its Phase 1/1b clinical study of eganelisib (IPI-549), a selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor. | infi-20201109.htm |
| 2020-09-29 | 8-K | 2020-09-29 | 8.01 Other Events | 8.01 On September 29, 2020, Infinity Pharmaceuticals, Inc., issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation for eganelisib in combination with a checkpoint inhibitor and chemotherapy for the treatment of inoperable locally advanced or metastatic triple-negative breast cancer. | infi-20200929.htm |
| 2020-08-25 | 8-K | 2020-08-24 | 8.01 Other Events | 8.01 As previously disclosed in the Current Report on Form 8-K of Infinity Pharmaceuticals, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “Commission”) on July 2, 2020, the Company received a notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, for the prior thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). | infi-20200824.htm |
| 2020-07-30 | 8-K | 2020-07-30 | 2.02 Results of Operations and Financial Condition | 2.02 On July 30, 2020, Infinity Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the quarter ended June 30, 2020 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20200730.htm |
| 2020-07-02 | 8-K | 2020-07-01 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On July 1, 2020, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). | a71208k.htm |
| 2020-06-18 | 8-K | 2020-06-17 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 3.03 The information contained in Item 5.03 below is incorporated by reference into this Item 3.03. 5.03 At the annual meeting of stockholders of Infinity Pharmaceuticals, Inc. (the “Company”) held on June 17, 2020 (the “2020 Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s common stock from 100,000,000 shares to 200,000,000 shares. | a618208k.htm |
| 2020-05-11 | 8-K | 2020-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2020, Infinity Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended March 31, 2020 and will conduct a previously announced, publicly available conference call to discuss those results. | a8k2020q110q.htm |
| 2020-04-07 | 8-K | 2020-04-07 | 8.01 Other Events | 8.01 On April 7, 2020, Infinity Pharmaceuticals, Inc. (the "Company"), issued a press release providing a business update in response to the COVID-19 pandemic. | a47208k.htm |
| 2020-03-25 | 8-K | 2020-03-25 | 8.01 Other Events | 8.01 On March 25, 2020, Infinity Pharmaceuticals, Inc., issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation for IPI-549 in combination with nivolumab for the treatment of advanced urothelial cancer. | a325208k.htm |
| 2020-03-17 | 8-K | 2020-03-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (d) On March 16, 2020, the Board of Directors (the “Board”) of Infinity Pharmaceuticals, Inc. (the “Company”), based on the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Richard Gaynor, M.D., as a director of the Company and appointed Dr. Gaynor to the Research and Development Committee (the “R&D Committee”) of the Board. 8.01 On March 17, 2020, the Company issued a press release announcing the election of Richard Gaynor to the Board. | a317208k.htm |
| 2020-03-03 | 8-K | 2020-02-27 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On March 3, 2020, Infinity Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the year ended December 31, 2019 and will conduct a previously announced, publicly available conference call to discuss those results. 5.02 (b) On February 27, 2020, Jeffery Kutok, M.D., Ph.D., Chief Scientific Officer and a named executive officer of the Company, notified the Company of his decision to resign effective March 31, 2020. | a201910kform8-kxfinancials.htm |
| 2020-01-13 | 8-K | 2020-01-13 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2019, the Company announced on January 13, 2020 that it expects to report that it had approximately $42.4 million in cash and investments (unaudited) as of December 31, 2019 and approximately $62 million in cash of January 8, 2020. 8.01 On January 13, 2020, Infinity Pharmaceuticals, Inc. issued a press release announcing its 2020 business goals and financial guidance. | d870449d8k.htm |
| 2020-01-09 | 8-K | 2020-01-08 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 On January 8, 2020 (the “Closing Date”) Infinity Pharmaceuticals, Inc. (the “Company”) entered into a funding agreement (the “Funding Agreement”) with BVF Partners, L.P., (“BVF”) and Royalty Security, LLC, a wholly owned subsidiary of BVF, (the “Buyer”) providing for the acquisition by the Buyer of the Company’s interest in all royalty payments based on worldwide annual net sales of the compound known as IPI-926, or patidegib (such compound known as the “Licensed Product”) less those royalty payments owed by Company to third parties including Purdue Pharmaceutical Products L.P. (“Purdue”) and Mundipharma International Corporation Limited (“MICL”) (“Third Party Royalty Obligations”) (all royalty payments less Third Party Royalty Obligations, “Royalty”). 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2019, the Company announced on January 9, 2020 that, following the receipt of the Upfront Purchase Price in the amount of $20.0 million (less certain transaction expenses) on the Closing Date, it had approximately $60.0 million in cash on hand. 2.03 The information provided in Item 1.01 under the heading “Funding Agreement” is hereby incorporated by reference into this Item 2.03. 3.02 The information provided in Item 1.01 under the heading “Potential Future Warrants” is hereby incorporated by reference into this Item 3.02. 7.01 On January 9, 2020, the Company issued a press release announcing the execution of the Funding Agreement and the transactions contemplated thereby. | d864299d8k.htm |